MedPath

National Institute of Siddha

🇮🇳India
Ownership
Private
Established
2005-01-01
Employees
-
Market Cap
-
Website
http://www.nischennai.org

Clinical Trials

687

Active:8
Completed:265

Trial Phases

5 Phases

Phase 1:24
Phase 2:285
Phase 3:151
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (583 trials with phase data)• Click on a phase to view related trials

Phase 2
285 (48.9%)
Phase 3
151 (25.9%)
Not Applicable
106 (18.2%)
Phase 1
24 (4.1%)
phase_2_3
9 (1.5%)
phase_1_2
6 (1.0%)
Phase 4
2 (0.3%)

Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai

Phase 2
Completed
Conditions
Tinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are Studied
Interventions
Drug: kandhaga rasayanam
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
National institute of Siddha
Target Recruit Count
50
Registration Number
NCT02238912
Locations
🇮🇳

National institute of siddha, Chennai, Tamilnadu, India

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.